rs1057519847
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Cytoplasmic ERβ1 expression is associated with survival of patients with Stage IV lung adenocarcinoma and an EGFR mutation at exon 21 L858R subsequent to treatment with EGFR-TKIs.
|
31289556 |
2019 |
rs1057519848
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Cytoplasmic ERβ1 expression is associated with survival of patients with Stage IV lung adenocarcinoma and an EGFR mutation at exon 21 L858R subsequent to treatment with EGFR-TKIs.
|
31289556 |
2019 |
rs121434568
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Cytoplasmic ERβ1 expression is associated with survival of patients with Stage IV lung adenocarcinoma and an EGFR mutation at exon 21 L858R subsequent to treatment with EGFR-TKIs.
|
31289556 |
2019 |
rs1057519847
|
|
|
0.040 |
GeneticVariation |
BEFREE |
A 65-year-old Japanese woman was diagnosed with stage IV lung adenocarcinoma with L858R point mutation in exon 21.
|
29675860 |
2018 |
rs1057519848
|
|
|
0.040 |
GeneticVariation |
BEFREE |
A 65-year-old Japanese woman was diagnosed with stage IV lung adenocarcinoma with L858R point mutation in exon 21.
|
29675860 |
2018 |
rs121434568
|
|
|
0.040 |
GeneticVariation |
BEFREE |
A 65-year-old Japanese woman was diagnosed with stage IV lung adenocarcinoma with L858R point mutation in exon 21.
|
29675860 |
2018 |
rs1057519847
|
|
|
0.040 |
GeneticVariation |
BEFREE |
We report a case of a 38-year-old woman who was diagnosed with stage IV lung adenocarcinoma, harboring an epidermal growth factor receptor (EGFR) L858R mutation on exon 21 and a T790 M mutation on exon 20.
|
27599705 |
2017 |
rs1057519848
|
|
|
0.040 |
GeneticVariation |
BEFREE |
We report a case of a 38-year-old woman who was diagnosed with stage IV lung adenocarcinoma, harboring an epidermal growth factor receptor (EGFR) L858R mutation on exon 21 and a T790 M mutation on exon 20.
|
27599705 |
2017 |
rs121434568
|
|
|
0.040 |
GeneticVariation |
BEFREE |
We report a case of a 38-year-old woman who was diagnosed with stage IV lung adenocarcinoma, harboring an epidermal growth factor receptor (EGFR) L858R mutation on exon 21 and a T790 M mutation on exon 20.
|
27599705 |
2017 |
rs1057519847
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Patients in stage IV lung adenocarcinoma with MPEs at initial diagnosis have shorter overall survival and higher EGFR mutation rate, especially for L858R, than patients who develop MPEs following disease progression.
|
23018906 |
2013 |
rs1057519848
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Patients in stage IV lung adenocarcinoma with MPEs at initial diagnosis have shorter overall survival and higher EGFR mutation rate, especially for L858R, than patients who develop MPEs following disease progression.
|
23018906 |
2013 |
rs121434568
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Patients in stage IV lung adenocarcinoma with MPEs at initial diagnosis have shorter overall survival and higher EGFR mutation rate, especially for L858R, than patients who develop MPEs following disease progression.
|
23018906 |
2013 |
rs149248025
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A 74-year-old woman was diagnosed with stage IV lung adenocarcinoma with EGFR L868R mutation 2 years before presentation.Gefitinib, an EGFR-TKI was started.
|
30868686 |
2019 |
rs121913444
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We present the case of a 68-year-old man with stage IV lung adenocarcinoma with an uncommon EGFR mutation in exon 21 (L861Q).
|
29866661 |
2018 |
rs397517096
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A Chinese woman diagnosed with stage IV lung adenocarcinoma harbored a rare EGFR L747P (2239-2240 TT > CC) mutation, and treatment with gefitinib and osimertinib failed to achieve the desired effect.
|
29673089 |
2018 |